Gujarat Inject Kerala Q1 FY27 results: EPS rises to Rs 1.28 vs Rs 0.86 YoY

Profit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.4%Reaction day

₹13.40

prior close

₹13.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+2.7% vs market

Pharmaceuticals peers, median of 165sector+0.0%+3.3% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+0.0

15m

-1.1

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.4+0.6+2.7+0.0+3.3

Next day

+0.0+0.2-0.2+0.0-0.0

-4.9-0.9-3.9-1.1-3.8

-5.2-0.3-4.9-0.4-4.8

-9.7+0.0-9.7-0.3-9.4

-14.2-1.1-13.0-1.6-12.6

-14.9-1.4-13.5-2.6-12.4

15d

-29.1+2.7-31.8-1.1-28.0

-0.8+3.6-4.4-0.4-0.4

-23.9+2.0-25.8-0.3-23.6

-28.4+1.1-29.4-2.2-26.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved unaudited Q1 FY27 results (quarter ended 30 June 2026). Basic and diluted EPS rose to Rs 1.28 from Rs 0.86 YoY, a jump of about 49 percent. Auditor S Mandawat and Co issued an unmodified limited review report with no qualifications. Company has only one reportable segment. Detailed revenue and PAT line items were not clearly legible in the filing.

Likely market impact

Strong 49 percent EPS growth and clean auditor report signal improved profitability; could be positive for the stock.